427 related articles for article (PubMed ID: 28751892)
1. Sharpening the Edge for Precision Cancer Immunotherapy: Targeting Tumor Antigens through Oncolytic Vaccines.
Holay N; Kim Y; Lee P; Gujar S
Front Immunol; 2017; 8():800. PubMed ID: 28751892
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment.
Feola S; Russo S; Ylösmäki E; Cerullo V
Pharmacol Ther; 2022 Aug; 236():108103. PubMed ID: 34954301
[TBL] [Abstract][Full Text] [Related]
3. Arming oncolytic viruses to leverage antitumor immunity.
de Gruijl TD; Janssen AB; van Beusechem VW
Expert Opin Biol Ther; 2015 Jul; 15(7):959-71. PubMed ID: 25959450
[TBL] [Abstract][Full Text] [Related]
4. Tumor-targeting oncolytic virus elicits potent immunotherapeutic vaccine responses to tumor antigens.
Luo Y; Lin C; Zou Y; Ju F; Ren W; Lin Y; Wang Y; Huang X; Liu H; Yu Z; Liu P; Tan G; Yuan Q; Zhang J; Huang C; Xia N
Oncoimmunology; 2020; 9(1):1726168. PubMed ID: 32117591
[TBL] [Abstract][Full Text] [Related]
5. Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements.
Yun CO; Hong J; Yoon AR
Front Immunol; 2022; 13():953410. PubMed ID: 36091031
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic viruses as therapeutic cancer vaccines.
Bartlett DL; Liu Z; Sathaiah M; Ravindranathan R; Guo Z; He Y; Guo ZS
Mol Cancer; 2013 Sep; 12(1):103. PubMed ID: 24020520
[TBL] [Abstract][Full Text] [Related]
7. Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine.
Feola S; Russo S; Martins B; Lopes A; Vandermeulen G; Fluhler V; De Giorgi C; Fusciello M; Pesonen S; Ylösmäki E; Antignani G; Chiaro J; Hamdan F; Feodoroff M; Grönholm M; Cerullo V
Front Immunol; 2022; 13():826164. PubMed ID: 35493448
[TBL] [Abstract][Full Text] [Related]
8. Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy.
Guo ZS; Lotze MT; Zhu Z; Storkus WJ; Song XT
Biomedicines; 2020 Jul; 8(7):. PubMed ID: 32664210
[TBL] [Abstract][Full Text] [Related]
9. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic Immunotherapy: Can't Start a Fire Without a Spark.
Muscolini M; Tassone E; Hiscott J
Cytokine Growth Factor Rev; 2020 Dec; 56():94-101. PubMed ID: 32826166
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives.
Guo ZS; Liu Z; Kowalsky S; Feist M; Kalinski P; Lu B; Storkus WJ; Bartlett DL
Front Immunol; 2017; 8():555. PubMed ID: 28555136
[TBL] [Abstract][Full Text] [Related]
12. Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies.
van Vloten JP; Workenhe ST; Wootton SK; Mossman KL; Bridle BW
J Immunol; 2018 Jan; 200(2):450-458. PubMed ID: 29311387
[TBL] [Abstract][Full Text] [Related]
13. Immunogenic cell death: The cornerstone of oncolytic viro-immunotherapy.
Palanivelu L; Liu CH; Lin LT
Front Immunol; 2022; 13():1038226. PubMed ID: 36755812
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity.
Guo ZS; Liu Z; Bartlett DL
Front Oncol; 2014; 4():74. PubMed ID: 24782985
[TBL] [Abstract][Full Text] [Related]
15. Systems Biology Approaches for the Improvement of Oncolytic Virus-Based Immunotherapies.
Tripodi L; Sasso E; Feola S; Coluccino L; Vitale M; Leoni G; Szomolay B; Pastore L; Cerullo V
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831638
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic Viruses-Natural and Genetically Engineered Cancer Immunotherapies.
Jhawar SR; Thandoni A; Bommareddy PK; Hassan S; Kohlhapp FJ; Goyal S; Schenkel JM; Silk AW; Zloza A
Front Oncol; 2017; 7():202. PubMed ID: 28955655
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors.
Feola S; Capasso C; Fusciello M; Martins B; Tähtinen S; Medeot M; Carpi S; Frascaro F; Ylosmäki E; Peltonen K; Pastore L; Cerullo V
Oncoimmunology; 2018; 7(8):e1457596. PubMed ID: 30221051
[TBL] [Abstract][Full Text] [Related]
19. A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines.
Feola S; Chiaro J; Martins B; Russo S; Fusciello M; Ylösmäki E; Bonini C; Ruggiero E; Hamdan F; Feodoroff M; Antignani G; Viitala T; Pesonen S; Grönholm M; Branca RMM; Lehtiö J; Cerullo V
Elife; 2022 Mar; 11():. PubMed ID: 35314027
[TBL] [Abstract][Full Text] [Related]
20. The role of oncolytic virus immunotherapies to subvert cancer immune evasion.
Workenhe ST; Verschoor ML; Mossman KL
Future Oncol; 2015; 11(4):675-89. PubMed ID: 25686121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]